Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Behnaz Abiri, Amirhossein Ramezani Ahmadi, Amir Ebadinejad, Farhad Hosseinpanah & Majid Valizadeh. (2022) Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight/obese individuals without diabetes: a systematic review and meta-analysis. Current Medical Research and Opinion 38:11, pages 1853-1863.
Read now
Read now
Anirudh Manoj, Subham Das, Anu Kunnath Ramachandran, Angel T Alex & Alex Joseph. (2020) SGLT2 inhibitors, an Accomplished Development in Field of Medicinal Chemistry: an Extensive Review. Future Medicinal Chemistry 12:21, pages 1961-1990.
Read now
Read now
Rosemarie Lajara. (2019) Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgraduate Medicine 131:8, pages 555-565.
Read now
Read now
Ernest Adeghate, Sahar Mohsin, Faisal Adi, Fares Ahmed, Ali Yahya, Huba Kalász, Kornelia Tekes & Ernest A. Adeghate. (2019) An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical
trials. Expert Opinion on Investigational Drugs 28:9, pages 811-820.
Read now
Read now
Articles from other publishers (34)
Aftab Ahmad & Hani Sabbour. (2024) Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Cardiovascular Diabetology 23:1.
Crossref
Crossref
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, Stanisław Surma, Krzysztof J. Filipiak & Aleksandra Gąsecka. (2023) The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?. Journal of Cardiovascular Development and Disease 10:11, pages 465.
Crossref
Crossref
Joana Costa d'Avila, Aluana Santana Carlos, Raimundo Lima Vieira, Carla Vergueiro, Aline Teixeira Lima, Isaias dos Santos Silva, Vivian Carvalho de Figueiredo, Paulo Henrique Petrone Chateaubriand, Adalgiza Mafra Moreno, Hugo Caire de Castro Faria Neto, Vanessa Estato & Rodrigo Azeredo Siqueira. (2023) Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats. Microcirculation 30:7.
Crossref
Crossref
Carolyn S.P. Lam, Chinthanie RamasundarahettigeKelley R.H. Branch, Naveed Sattar, Julio RosenstockRichard Pratley, Stefano Del Prato, Renato D. Lopes, Elisabeth NiemoellerNardev S. Khurmi, Seungjae Baek & Hertzel C. Gerstein. (2022) Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation 145:8, pages 565-574.
Crossref
Crossref
Chen Li, Jie Luo, Mingyan Jiang & Keke Wang. (2022) The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Ilora Bandyopadhyay, Sunny Dave, Amita Rai, Madhavan Nampoothiri, Mallikarjuna Rao Chamallamudi & Nitesh Kumar. (2022) Oral Semaglutide in the Management of Type 2 DM: Clinical Status and
Comparative Analysis. Current Drug Targets 23:3, pages 311-327.
Crossref
Crossref
Worood Sirhan & Ron Piran. 2022. Peptide and Peptidomimetic Therapeutics. Peptide and Peptidomimetic Therapeutics
521
550
.
Yun Kyung Cho, Ye-Jee Kim & Chang Hee Jung. (2021) Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis. Journal of Obesity & Metabolic Syndrome 30:4, pages 336-344.
Crossref
Crossref
Marvin Wei Jie Chua. (2021) High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination. Clinics and Practice 12:1, pages 1-7.
Crossref
Crossref
Karen E Elkind-Hirsch, N Chappell, Ericka Seidemann, John Storment & Drake Bellanger. (2021) Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism 106:10, pages 3019-3033.
Crossref
Crossref
Tatiana Valente & Alberto K. Arbex. (2021) Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus. Current Diabetes Reviews 17:7.
Crossref
Crossref
Yanting Ding, Sijing Xia, Han Zhang, Qin Chen & Bing Niu. (2020) Loureirin B activates GLP‐1R and promotes insulin secretion in Ins‐1 cells. Journal of Cellular and Molecular Medicine 25:2, pages 855-866.
Crossref
Crossref
Shubing Jia, Zhiying Wang, Ruobing Han, Zinv Zhang, Yuping Li, Xiaotong Qin, Mingyi Zhao, Rongwu Xiang & Jingyu Yang. (2020) Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. Acta Diabetologica 58:1, pages 5-18.
Crossref
Crossref
Worood Sirhan & Ron Piran. (2020) Current Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia. Current Topics in Medicinal Chemistry 20:32, pages 2922-2944.
Crossref
Crossref
Serge A. Jabbour, Juan P. Frías, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C. David Sjöström & Cristian Guja. (2020) Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care 43:10, pages 2528-2536.
Crossref
Crossref
John E. Anderson. (2020) Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. Diabetes Spectrum 33:2, pages 165-174.
Crossref
Crossref
Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli & Laura Fumagalli. (2020) Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules 25:8, pages 1987.
Crossref
Crossref
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono, Yuichi Nozaki, Hideyuki Hyogo, Masahiro Koseki, Yuichi Yoshida, Takumi Kawaguchi, Yoshihiro Kamada, Takeshi Okanoue & Atsushi Nakajima. (2020) Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences 21:6, pages 1907.
Crossref
Crossref
Man Guo, Junling Gu, Fangyuan Teng, Jiao Chen, Xiumei Ma, Qing Chen, Yueli Pu, Zongzhe Jiang, Yang Long & Yong Xu. (2020) The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine 67:2, pages 294-304.
Crossref
Crossref
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas & Christos S. Mantzoros. (2020) Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology 18:2, pages 172-181.
Crossref
Crossref
Hitomi Sano, Eriko Kudo, Takeshi Yamazaki, Tomoshiro Ito, Kinya Hatakeyama & Nobuaki Kawamura. (2020) Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report. Clinical Pediatric Endocrinology 29:2, pages 81-84.
Crossref
Crossref
Marco Castellana, Angelo Cignarelli, Francesco Brescia, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola & Francesco Giorgino. (2019) Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Scientific Reports 9:1.
Crossref
Crossref
V. V. Salukhov. (2019) The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination. Medical Council:4, pages 44-51.
Crossref
Crossref
Maria J. Pereira & Jan W. Eriksson. (2019) Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs 79:3, pages 219-230.
Crossref
Crossref
Mariangela Ucci, Pamela Di Tomo, Federica Tritschler, Vincenzo G. P. Cordone, Paola Lanuti, Giuseppina Bologna, Sara Di Silvestre, Natalia Di Pietro, Caterina Pipino, Domitilla Mandatori, Gloria Formoso & Assunta Pandolfi. (2019) Anti-inflammatory Role of Carotenoids in Endothelial Cells Derived from Umbilical Cord of Women Affected by Gestational Diabetes Mellitus. Oxidative Medicine and Cellular Longevity 2019, pages 1-11.
Crossref
Crossref
Farzaneh Maleki, Puneet Gaitonde, Shannon Miller, Mirjam N. Trame, Paul M. Coen, Parag Garhyan & Stephan Schmidt. 2019. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease
449
466
.
André J. Scheen. (2018) Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Research and Clinical Practice 143, pages 88-100.
Crossref
Crossref
Maria J. Pereira, Per Lundkvist, Prasad G. Kamble, Joey Lau, Julian G. Martins, C. David Sjöström, Volker Schnecke, Anna Walentinsson, Eva Johnsson & Jan W. Eriksson. (2018) A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss. Diabetes Therapy 9:4, pages 1511-1532.
Crossref
Crossref
Serge A. Jabbour, Juan P. Frías, Cristian Guja, Elise Hardy, Azazuddin Ahmed & Peter Öhman. (2018) Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study. Diabetes, Obesity and Metabolism 20:6, pages 1515-1519.
Crossref
Crossref
André J. Scheen. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research 122:10, pages 1439-1459.
Crossref
Crossref
Milton Packer. (2018) Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?. The American Journal of Medicine 131:5, pages 461-463.
Crossref
Crossref
A.J. Scheen. (2018) Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années. Médecine des Maladies Métaboliques 12:2, pages 174-181.
Crossref
Crossref
Mohammed Bensellam, Jean-Christophe Jonas & D Ross Laybutt. (2018) Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions. Journal of Endocrinology 236:2, pages R109-R143.
Crossref
Crossref
Yukio Horikawa, Mayumi Enya, Makie Komagata, Ken-ichi Hashimoto, Masayo Kagami, Maki Fukami & Jun Takeda. (2018) Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader–Willi Syndrome: A Case Report. Diabetes Therapy 9:1, pages 421-426.
Crossref
Crossref